BLCOBausch + Lomb demonstrates a solid position in the eye health sector with a diversified product range. However, recent financial performance shows profitability challenges, and technical indicators suggest a cautious outlook. A balanced approach considering its stable market presence and potential turnaround is recommended.
The aging global population and increasing awareness of eye care present long-term tailwinds for Bausch + Lomb. Emerging markets and advancements in ophthalmic technology offer growth avenues, though competition and regulatory hurdles are present.
Bausch + Lomb demonstrates robust revenue streams across its segments. However, recent net losses and negative free cash flow are concerning. The company holds significant assets, but debt levels have increased, impacting financial leverage.
The stock price has experienced a significant decline over the past year and shows weakness across multiple timeframes. Key moving averages are signaling downward momentum, and most oscillators suggest a bearish trend.
| Factor | Score |
|---|---|
| Aging Population & Eye Health Awareness | 80 |
| Technological Advancements in Vision Care | 75 |
| Market Penetration in Emerging Markets | 60 |
| Regulatory Landscape & Competition | 40 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 55 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 45 |
| Support & Resistance | 70 |
Earnings Surprise
Bausch + Lomb Corporation has exceeded earnings per share (EPS) estimates in 7 out of the last 10 quarters, with a notable average positive surprise of 21.8% in Q3 2023.
Attractive Price-to-Sales Ratio
The current Price-to-Sales (PS) ratio of 1.4 is below its trailing four-quarter average of 1.5 and competitive within the eye health industry.
Negative Net Income
Bausch + Lomb Corporation has reported a net loss for the trailing twelve months (TTM) of -$211 million and for the fiscal year 2024 (-$317 million), indicating profitability challenges.
Negative P/E Ratio
The company has a negative Price-to-Earnings (P/E) ratio (TTM: -23.4, FY2024: -20.1), which is a strong indicator of current unprofitability and makes traditional P/E analysis unreliable.
July 2025
30
Next Earnings Date
H: $0.37
A: $0.09
L: $-0.01
H: 1.28B
A: 1.25B
L: 1.21B
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
14.29 USD
The 39 analysts offering 1 year price forecasts for BLCO have a max estimate of 18.00 and a min estimate of 11.00.